Grifols SA, Barcelona (GRFS) and Tetralogic Pharmaceuticals (TLOG) Head-To-Head Analysis
Grifols SA, Barcelona (NASDAQ: GRFS) and Tetralogic Pharmaceuticals (OTCMKTS:TLOG) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.
Grifols SA, Barcelona pays an annual dividend of $0.28 per share and has a dividend yield of 1.3%. Tetralogic Pharmaceuticals does not pay a dividend. Grifols SA, Barcelona pays out 30.1% of its earnings in the form of a dividend.
Earnings & Valuation
This table compares Grifols SA, Barcelona and Tetralogic Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Grifols SA, Barcelona||$4.48 billion||3.34||$603.60 million||$0.93||23.55|
|Tetralogic Pharmaceuticals||N/A||N/A||-$49.72 million||($1.65)||-0.03|
Grifols SA, Barcelona has higher revenue and earnings than Tetralogic Pharmaceuticals. Tetralogic Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols SA, Barcelona, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations for Grifols SA, Barcelona and Tetralogic Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Grifols SA, Barcelona||0||1||3||0||2.75|
This table compares Grifols SA, Barcelona and Tetralogic Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Grifols SA, Barcelona||13.16%||18.08%||6.22%|
Institutional and Insider Ownership
22.5% of Grifols SA, Barcelona shares are owned by institutional investors. Comparatively, 0.0% of Tetralogic Pharmaceuticals shares are owned by institutional investors. 15.4% of Tetralogic Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility & Risk
Grifols SA, Barcelona has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500.
Grifols SA, Barcelona beats Tetralogic Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
About Grifols SA, Barcelona
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
About Tetralogic Pharmaceuticals
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.